Clin2
NCT07575672Possibly a fitNot yet recruiting

Finerenone for Heart Failure Patients Getting Aortic Valve Surgery

HFpEF - Heart Failure With Preserved Ejection FractionTAVI(Transcatheter Aortic Valve Implantation)Finerenone

Treatments studied

Part of Heart & circulation clinical trials.

This trial tests whether a medication called finerenone can help patients with heart failure who are having a minimally invasive procedure (TAVI) to replace a narrowed aortic valve. The goal is to see if this drug reduces heart problems after the valve procedure.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
2,832 people
Ages
65 years and older
Study type
Interventional

Who can take part

  • You are age 65 or older
  • You have severe aortic stenosis (a narrowed heart valve) and are scheduled for a transcatheter aortic valve implant (TAVI—a less invasive valve replacement)
  • You have heart failure symptoms that limit your activity (New York Heart Association class II or higher)
  • Your heart's pumping strength is at least 40% (measured by ejection fraction)
  • Your kidney function is adequate (eGFR ≥ 25 mL/min/1.73 m²) and your potassium level is controlled (≤ 5.0 mmol/L)
  • You have not had a heart attack, stroke, or certain cardiac procedures in the past 30 days

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06008197Recruiting· Phase 3
A study of finerenone for hospitalized heart failure patients

This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.

Birmingham, Alabama
NCT07583173Not yet recruiting· Phase 4
Finerenone for heart failure with preserved ejection fraction

This study tests whether a medication called finerenone can reduce scarring in the heart and improve heart function in people with heart failure who have ejection fractions of 40% or higher. You may be eligible if you've recently had heart failure symptoms requiring emergency care or medication changes.

Beijing
NCT06033950Recruiting· Phase 3
A study of finerenone for heart failure patients who can't take standard MRA drugs

This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.

Fairhope, Alabama
NCT07397650Recruiting· Phase 4
Early finerenone for heart failure in hospital

This trial tests if starting finerenone early helps patients hospitalized with heart failure who have symptoms like shortness of breath or swelling. It aims to see if the drug is safe and effective when given soon after admission.

Handa, Aichi-ken
NCT07270367Not yet recruiting· Phase 3
Finerenone study for heart thickening

This trial tests if a medication called finerenone can improve heart structure and function in people whose heart walls are thickened. It may help people with early heart failure or related conditions like diabetes or kidney disease.

Cambridge, Ontario
NCT07442448Enrolling by invitation· Phase 4
Study of Finerenone for heart and kidney health in diabetes

This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.

Taipei

Hear when a new TAVI(Transcatheter Aortic Valve Implantation) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.